Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

WOCKHARDT LTD.

NSE : WOCKPHARMABSE : 532300ISIN CODE : INE049B01025Industry : Pharmaceuticals & DrugsHouse : Wockhardt

BSE1496.7537.1 (+2.54 %)

PREV CLOSE ( ) 1459.65

OPEN PRICE ( ) 1462.00

BID PRICE (QTY) 0.00 (0)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 31015

TODAY'S LOW / HIGH ( )1462.00 1536.35

52 WK LOW / HIGH ( )918.85 1870

NSE1493.7033.1 (+2.27 %)

PREV CLOSE( ) 1460.60

OPEN PRICE ( ) 1460.60

BID PRICE (QTY) 1493.70 (10289)

OFFER PRICE (QTY) 0.00 (0)

VOLUME 521730

TODAY'S LOW / HIGH( ) 1460.60 1535.40

52 WK LOW / HIGH ( )915 1868.8

Select year

Particulars

Mar 2025

Mar 2024

Mar 2023

Mar 2022

Mar 2021

Operational & Financial Ratios

Earnings Per Share (Rs)

-2.90

-30.06

-38.82

-16.94

62.36

CEPS(Rs)

9.88

-16.17

-25.69

-2.22

-4.27

DPS(Rs)

0.00

Book NAV/Share(Rs)

267.96

217.27

231.81

266.04

304.36

Tax Rate(%)

-256.25

-12.38

0.48

32.12

47.71

Margin Ratios

Core EBITDA Margin(%)

10.16

1.08

2.36

5.81

-1.36

EBIT Margin(%)

6.15

-3.19

-7.54

-2.18

-6.88

Pre Tax Margin(%)

-0.41

-11.65

-14.60

-8.01

-12.25

PAT Margin (%)

-1.47

-13.09

-14.53

-5.44

-6.41

Cash Profit Margin (%)

4.14

-6.91

-8.66

-0.62

-1.10

Performance Ratios

ROA(%)

-0.78

-6.67

-8.42

-3.71

-3.93

ROE(%)

-1.48

-14.12

-17.32

-7.77

-9.92

ROCE(%)

4.07

-2.15

-5.88

-1.96

-5.50

Asset Turnover(x)

0.53

0.51

0.58

0.68

0.61

Sales/Fixed Asset(x)

0.67

0.63

0.73

0.88

0.75

Working Capital/Sales(x)

9.16

-5.02

-2.81

-6.73

-5.52

Efficiency Ratios

Fixed Capital/Sales(x)

1.49

1.58

1.37

1.14

1.33

Receivable days

60.36

71.63

73.25

65.29

85.04

Inventory Days

64.42

65.71

60.95

55.76

59.63

Payable days

218.94

255.81

293.71

232.91

255.87

Valuation Parameters

PER(x)

0.00

6.64

PCE(x)

144.15

-36.09

-5.99

-118.71

-89.37

Price/Book(x)

5.31

2.69

0.66

0.99

1.36

Yield(%)

0.00

EV/Net Sales(x)

8.21

3.78

1.50

1.63

2.44

EV/Core EBITDA(x)

54.36

86.64

17.85

16.52

95.62

EV/EBIT(x)

103.92

-91.91

-12.36

-46.92

-20.68

EV/CE(x)

3.98

1.93

0.76

0.69

0.89

M Cap / Sales

7.66

3.21

0.84

1.18

1.68

Growth Ratio

Net Sales Growth(%)

7.65

5.55

-17.93

19.28

-4.78

Core EBITDA Growth(%)

272.95

-45.29

-29.87

360.87

-56.28

EBIT Growth(%)

306.96

64.29

-187.50

64.89

-381.15

PAT Growth(%)

87.92

23.99

-122.58

6.06

-115.30

EPS Growth(%)

90.35

22.55

-129.10

-127.17

1097.71

Financial Stability Ratios

Total Debt/Equity(x)

0.43

0.63

0.57

0.49

0.70

Current Ratio(x)

1.21

0.74

0.56

0.76

0.73

Quick Ratio(x)

0.85

0.51

0.37

0.52

0.47

Interest Cover(x)

0.94

-0.38

-1.07

-0.37

-1.28

Total Debt/Mcap(x)

0.08

0.24

0.85

0.49

0.51